Determination of antipsychotic drugs and mood stabilizers cotreatments at greater risks of weight gain: analysis in two clinical cohorts

Diplôme Master Determination of antipsychotic drugs and mood stabilizers cotreatments at greater risks of weight gain: analysis in two clinical cohorts eng 2017 author Pelloni Lisa 823787 director Eap Chin Bin 648560 Schizophrenic, bipolar and depressive patients represent a psychiatric population at greater risk of metabolic syndrome and experience diabetes and obesity at twice the rate that the general population does. Hence, individuals with serious mental illness have 20% shorter lifespan compared to the general population1. Elevation in cardiovascular mortality, which represents the leading cause of death, has been reported for schizophrenia and bipolar disorder as illustrated in S1 Figure 2. The association between cardiovascular risk and bipolar disorder is comparable to the association between cardiovascular risk and schizophrenia3. Cardiovascular diseases are an ultimate consequence of all the factors co-occurring in these psychiatric diseases, including pharmacological treatments, the lifestyle of patients but also genetic and physiological factors. Dewey 615 Master en Pharmacie 31 Section des sciences pharmaceutiques 17 false e2761f31-11ad-4a69-9558-d61fd7ea6a87 Master thesis Restricted 170616145617_pellonl2__TPR.pdf 1953738 application/pdf restrictedAccess Faculté des sciences / Section des sciences pharmaceutiques

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Determination of antipsychotic drugs and mood stabilizers cotreatments at greater risks of weight gain: analysis in two clinical cohorts				2017	104	2

Archive ouverte UNIGE

Pelloni, Lisa